Is HLA Donor-Specific Antibody (DSA)-C3d+ Assay a Potential Predictor of Subclinical Antibody Mediated Damage in the Renal Graft?

A. G. Contreras¹, M. I. Solis-G¹, C. Ramirez-Espinoza¹, J. Hernandez-Rosales², M. Vilatoba-Chapa¹, R. Cruz-Martínez¹, J. Granados¹, L. E. Morales-Buenrostro³, J. Alberú¹, J. M. Arreola-Guerra⁴

¹Transplantation, Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico, ²Department of Histocompatibility, Laboratorio Clinico del Campestre, Mexico City, Mexico, ³Nephrology-Mineral Metabolism, Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico, ⁴Internal Medicine, Centenario Hospital Miguel Hidalgo, Mexico City, Mexico

Meeting: 2019 American Transplant Congress

Abstract number: D113

Keywords: Alloantibodies, Biopsy, Kidney transplantation, Rejection

Session Information

Session Name: Poster Session D: Kidney Acute Antibody Mediated Rejection

Session Type: Poster Session

Date: Tuesday, June 4, 2019

Session Time: 6:00pm-7:00pm

Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

*Purpose: The Aim of the study was to explore the predictive value of the C3d assay for tissue damage in kidney transplant recipients (KTR) in whom DSA were detected during follow-up and in whom protocol biopsies (PBx) were performed.

*Methods: To 76 adult KTR, 40 female and 36 male, with DSA documented by SAB (Luminex) (n=2.1 (±1.2) a PBx was performed at a mean post-KT time of 4.8 years. C3d assay was carried out in sera frozen corresponding to the sample when DSA-SAB were detected.

*Results: DSA class I, class II and both were detected in 24 (31.5 %) and 52 (68.4 %) respectively, with MFI of immunodominant DSA of 1,673 (IQR 919 – 2852). DSA-C3d were positive in 14 (18.4%) KTR an only 6 (7.8 %) were donor specific all of them against HLA-DQ and HLA-DR. PBx classified according to BANFF 2013 disclosed: Subclinical AMR in 9 (11.8 %), Borderline lesions in 35 (46 %), subclinical acute cellular rejection (SACR) in 2 (2.6 %) and no significant findings in the remaining PBx.

*Conclusions: C3d assay was not predictive of subclinical antibody mediated rejection. C3d positivity was no related to DSA-MFI neither to the alloantibody class.

To cite this abstract in AMA style:

Contreras AG, Solis-G MI, Ramirez-Espinoza C, Hernandez-Rosales J, Vilatoba-Chapa M, Cruz-Martínez R, Granados J, Morales-Buenrostro LE, Alberú J, Arreola-Guerra JM. Is HLA Donor-Specific Antibody (DSA)-C3d+ Assay a Potential Predictor of Subclinical Antibody Mediated Damage in the Renal Graft? [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/is-hla-donor-specific-antibody-dsa-c3d-assay-a-potential-predictor-of-subclinical-antibody-mediated-damage-in-the-renal-graft/. Accessed November 22, 2024.

« Back to 2019 American Transplant Congress